Titanium dioxide
In clinical developmentAlso known as CI 77891, dióxido de titanio, óxido de titanio(4).
Recent clinical, regulatory, research and industry developments relating to this drug.
The effect of green carbon Dots/Titanium dioxide for photocatalytic reduction of CO2
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- Journal of nanobiotechnology1
- Ashrafizadeh M1
- Han M1
- Hou Y1
- Liu T1
- Orive G1
- Tian Y1
- Yang L1
- Yang Y1
- Biomedical Research Networking Centre in Bioengineering1
- Harbin Medical University Cancer Hospital1
- Hepato-Pancreato-Biliary Center1
- Hunan University of Medicine General Hospital1
- Key Laboratory of Brain and Cognitive Neuroscience1
- School of Pharmacy1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Titanium dioxide in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials